Press Releases for AFFY

Press Releases
Affymax Announces Close of Common Stock Offering and Exercise of Underwriters' Overallotment Option
Affymax Announces Proposed Public Offering of Common Stock
Affymax® Reports Third Quarter 2009 Financial Results
Affymax Secures $60 Million Issuer Managed Equity Facility With Azimuth Opportunity, Ltd.
Affymax® Reports Second Quarter 2009 Financial Results
Affymax Announces Data Monitoring Committee Review of Phase 3 Hematide Program
Affymax Appoints Hollings C. Renton to Board of Directors
Affymax Announces Another Data Monitoring Committee Review of Phase 3 Hematide Program
Affymax® Reports Phase 2 Clinical Trial Data Supporting Hemoglobin Increases with Once-Per-Month Hematide™ Regardless of Patient Baseline Renal Function
Affymax® Reports First Quarter 2009 Financial Results
Affymax Reports Phase 2 Sub-Analysis of Hematide™ in Hemodialysis Patients
Affymax to Present at Citi’s 4th Annual Biotech Day
Affymax® Reports Year End 2008 Financial Results - Business Wire
Affymax® Reports Year End 2008 Financial Results - Business Wire
Affymax Announces Upcoming Webcasts and Conference Participation - Mar 2 2009 8:22AM
Affymax Announces $42 Million Private Placement
Affymax to Present at BIO CEO and Investor Conference
Affymax to Present at RBC Capital Markets Healthcare Conference
Affymax Announces Another Favorable Data Monitoring Committee Review of Phase 3 Hematide Program
Affymax, Inc. (AFFY) Executive Officer to Ring the NASDAQ Stock Market Closing Bell
Affymax Completes Enrollment in Phase 3 Program for Hematide in Chronic Renal Failure with Completion of Enrollment in EMERALD 2, the Final of Four Phase 3 Clinical Trials of Hematide(TM)
Affymax to Present at Lazard Capital Markets Conference
Affymax to Webcast Analyst and Investor Event on November 20, 2008
Affymax Completes Enrollment in EMERALD 1, the Third of Four Phase 3 Clinical Trials of Hematide(TM) to Treat Anemia in Chronic Renal Failure Patients
Affymax Announces New Data Presented on the Long-Term Safety and Effectiveness of Hematide(TM) to Treat Anemia in Chronic Renal Failure Patients with Monthly Dosing
Affymax(R) Reports Third Quarter 2008 Financial Results
Affymax Completes Enrollment in PEARL 2, the Second of Four Phase 3 Clinical Trials of Hematide to Treat Anemia in Chronic Renal Failure Patients
Affymax Announces Upcoming Webcasts and Conference Participation - Oct 23 2008 8:29AM
Affymax to Present at UBS Global Life Sciences Conference
Affymax to Hold Conference Call and Webcast to Provide Clinical Development Update at 5:00 P.M. Eastern Time
Takeda and Affymax Provide Clinical Development Update for Hematide(TM) in Chemotherapy-Induced Anemia
Affymax Announces Upcoming Webcasts and Conference Participation - Aug 28 2008 8:21AM
Affymax(R) Reports Second Quarter 2008 Financial Results
Affymax Announces Favorable Data Monitoring Committee Review of Phase 3 Hematide Program
Affymax Announces Upcoming Webcasts and Conference Participation - Jul 28 2008 8:14AM
Affymax Completes Enrollment in PEARL 1, the First of Four Phase 3 Clinical Trials of Hematide(TM) to Treat Anemia in Chronic Renal Failure Patients
Affymax Initiates Clinical Trial of Hematide(TM) to Evaluate Correction of Anemia in Chronic Renal Failure Patients on Dialysis
Affymax(R) Announces Executive Management Promotions
Affymax and Takeda Announce Long-Term Hematide Safety and Effectiveness Data from Phase 2 Clinical Trials in Chronic Kidney Disease Patients with Anemia - Jun 1 2008 6:49AM
Affymax(R) Reports First Quarter 2008 Financial Results - Jun 1 2008 6:48AM
Affymax Announces Upcoming Webcasts and Conference Participation - Jun 1 2008 6:47AM
Affymax Appoints Vice President, Biostatistics and Data Management
Affymax and Takeda Report Long-Term Safety and Effectiveness Data of Hematide in Chronic Renal Failure Patients With Anemia